Mitani, Seiichiro
Kadowaki, Shigenori http://orcid.org/0000-0001-9923-5309
Hasegawa, Hiroko
Wakatsuki, Takeru
Hara, Hiroki
Tajika, Masahiro
Nishikawa, Kazuhiro
Hirao, Motohiro
Takahari, Daisuke
Chin, Keisho
Muro, Kei
Article History
Received: 27 January 2019
Accepted: 22 May 2019
First Online: 31 May 2019
Compliance with ethical standards
:
: Seiichiro Mitani has received honoraria from Eli Lilly. Shigenori Kadowaki has received honoraria from Eli Lilly, Bayer, Bristol-Myers, Chugai, Ono, and Yakult, and research funding from Eli Lilly, Boehringer Ingelheim, Bristol-Myers, Ono, and Taiho. Hiroki Hara has received honoraria from Chugai, Taiho, Merck Serono, Yakult, Eli Lilly, Ono, Takeda, Bristol-Myers, and research funding from AstraZeneca, Chugai, Merck Serono, MSD, Ono, Taiho, Takeda, Boehringer Ingelheim, Dainippon Sumitomo, Daiichi Sankyo, Eli Lilly, Pfizer, LSK BioPharma, Eisai, and Incyte. Kazuhiro Nishikawa has received honoraria from Chugai, Taiho, Yakult, Eli Lilly, Tsumura, and EA Pharma, and research funding from Yakult and Taiho. Kei Muro has received honoraria from Eli Lilly, Chugai, Merck Serono, Ono, Taiho, Takeda, and Yakult, and research funding from Daiichi Sankyo, Gilead Sciences, Kyowa Hakko Kirin, MSD, Ono, and Shionogi. None of the remaining authors have potential conflicts of interest to declare.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.